LIVN Reiterated by Piper Sandler -- Price Target Raised to $90

gurufocus.com · 2026-09-02

On September 2, 2026, Piper Sandler analyst Adam Maeder reiterated an Overweight rating for LivaNova (LIVN). The firm has raised its price target from $87.00 to

TickrTrends take: Piper Sandler's reiterated coverage and price target increase to $90 provide external validation for LIVN's current positioning within the Healthcare sector. Given TickrTrends' assessment that the stock is fairly valued at present, investors monitoring valuation metrics should track whether the analyst's elevated price target reflects near-term catalysts or longer-term growth expectations that could shift the fair value perception. The gap between current market levels and the $90 target may indicate whether consensus views LIVN as offering upside potential relative to its intrinsic value fundamentals.

Read the full story at gurufocus.com →